Department of Pulmonology, Centro Hospitalar e Universitário São João.
Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro.
Anticancer Drugs. 2021 Jun 1;32(5):567-574. doi: 10.1097/CAD.0000000000001060.
Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified Glasgow Prognostic Score (mGPS) and neutrophil-to-lymphocyte ratio (NLR) was assessed. From 77 patients included, 83.2% received at least one prior systemic therapy. Immune-related adverse events (irAE) occurred in 20 patients. A lower mGPS was associated with higher median overall survival (OS), and a lower Eastern Cooperative Oncology Group (ECOG), irAE and fewer metastatic sites with better survival. A trend towards greater OS and progression-free survival (PFS) was stated among patients with NLR <5. mGPS 0 was associated with better survival; ≥3 metastatic sites with worse PFS and OS; ECOG >2 with worse OS and irAE with better survival. Pretreatment mGPS seems to be useful for predicting survival among advanced NSCLC patients treated with anti-programmed cell death 1 drugs, with ECOG performance status, irAE occurrence, and number of metastatic sites acting as survival predictors.
免疫检查点抑制剂已被批准用于治疗晚期非小细胞肺癌（NSCLC）。尽管生存得到了改善，但并非所有患者都能从这些药物中获益。在这里，评估了预处理改良格拉斯哥预后评分（mGPS）和中性粒细胞与淋巴细胞比值（NLR）的预后影响。在纳入的 77 名患者中，83.2%接受了至少一次系统治疗前治疗。20 名患者发生免疫相关不良事件（irAE）。较低的 mGPS 与更高的中位总生存期（OS）相关，ECOG 评分更低、irAE 更少、转移部位更少的患者具有更好的生存。 NLR<5 的患者 OS 和无进展生存期（PFS）更长。mGPS 0 与更好的生存相关；≥3 个转移部位与更差的 PFS 和 OS 相关；ECOG >2 与更差的 OS 和 irAE 与更好的生存相关。在接受抗程序性细胞死亡 1 药物治疗的晚期 NSCLC 患者中，预处理 mGPS 似乎可用于预测生存，ECOG 表现状态、irAE 发生和转移部位数量是生存的预测因素。
